Metrics to compare | 688289 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688289PeersSector | |
|---|---|---|---|---|
P/E Ratio | 66.7x | 28.7x | −0.3x | |
PEG Ratio | −1.29 | −1.81 | 0.00 | |
Price/Book | 1.3x | 2.1x | 2.6x | |
Price / LTM Sales | 5.6x | 5.5x | 2.9x | |
Upside (Analyst Target) | 38.9% | 28.0% | 66.7% | |
Fair Value Upside | Unlock | 4.4% | 9.6% | Unlock |
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers respiratory tract infections, reproductive tract infections, blood-borne infections, gastrointestinal infections, vector-borne diseases and others, DNA/RNA extraction reagents, sample storage reagent, extraction instruments, PCR instruments, mPOCT. The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems. The company was founded in 2008 and is headquartered in Changsha, China.